Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers

Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417
Hauptverfasser: Bayerdörffer, Ekkehard, Miehlke, Stephan, Mannes, Gerd A., Sommer, Albrecht, Höchter, Wilhelm, Weingart, Josef, Heldwein, Walter, Klann, Hermann, Simon, Thomas, Schmitt, Wolfgang, Bästlein, Elke, Eimiller, Albert, Hatz, Rudolf, Lehn, Norbert, Dirschedl, Peter, Stolte, Manfred
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1417
container_issue 5
container_start_page 1412
container_title Gastroenterology (New York, N.Y. 1943)
container_volume 108
creator Bayerdörffer, Ekkehard
Miehlke, Stephan
Mannes, Gerd A.
Sommer, Albrecht
Höchter, Wilhelm
Weingart, Josef
Heldwein, Walter
Klann, Hermann
Simon, Thomas
Schmitt, Wolfgang
Bästlein, Elke
Eimiller, Albert
Hatz, Rudolf
Lehn, Norbert
Dirschedl, Peter
Stolte, Manfred
description Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with that achieved with “triple therapy.” Methods In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131). Results Cure rates of H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in H. pylori -negative and 49% in H. pylori-positive patients. Conclusions The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.
doi_str_mv 10.1016/0016-5085(95)90689-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77232285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0016508595906894</els_id><sourcerecordid>77232285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</originalsourceid><addsrcrecordid>eNp9kN-LFSEUxyVattvWf1DgQ0Q9zKaOztWXhdh-7MJCL_Usjh7JcMZJnXa3vz6He7mPgejB8zlfDh-EXlFySQkdPpB2dYJI8U6J94oMUnX8CdpRwWTXeuwp2p2QZ-h5Kb8IIaqX9Byd7_dMDX2_Q_ef0jpG6MYYZodrDibi5HGaYMnmb4qATfs3U3oINsQG4ZqwXTPgG4jBptHYChkvjzHlgMPswdaQ5lbhxdQAcy34PtSf2K3JwdzS12ghlxfozJtY4OXxvUA_vnz-fn3T3X37env98a6zvGe1G0EJ6yVjkvSDJxy4kGD9ICwhzhHqODAulXOSA6HSskGCUXaruPJ831-gt4fcJaffK5Sqp1AsxGhmSGvRTUTf0kUD-QG0OZWSweslh8nkR02J3nzrTabeZGrVzuZb8zb2-pi_jhO409BRcOu_OfZNsSb6bGYbygnrBWOUbDFXBwyaiz8Bsi62ybPgQm5GtUvh_3v8A8LknaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77232285</pqid></control><display><type>article</type><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</creator><creatorcontrib>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</creatorcontrib><description>Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with that achieved with “triple therapy.” Methods In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131). Results Cure rates of H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in H. pylori -negative and 49% in H. pylori-positive patients. Conclusions The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(95)90689-4</identifier><identifier>PMID: 7729633</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Amoxicillin - administration &amp; dosage ; Biological and medical sciences ; Double-Blind Method ; Drug Therapy, Combination ; Duodenal Ulcer - drug therapy ; Duodenal Ulcer - etiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Germany ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Male ; Medical sciences ; Middle Aged ; Omeprazole - administration &amp; dosage ; Other diseases. Semiology ; Recurrence ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417</ispartof><rights>1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</citedby><cites>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0016-5085(95)90689-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3522104$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7729633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayerdörffer, Ekkehard</creatorcontrib><creatorcontrib>Miehlke, Stephan</creatorcontrib><creatorcontrib>Mannes, Gerd A.</creatorcontrib><creatorcontrib>Sommer, Albrecht</creatorcontrib><creatorcontrib>Höchter, Wilhelm</creatorcontrib><creatorcontrib>Weingart, Josef</creatorcontrib><creatorcontrib>Heldwein, Walter</creatorcontrib><creatorcontrib>Klann, Hermann</creatorcontrib><creatorcontrib>Simon, Thomas</creatorcontrib><creatorcontrib>Schmitt, Wolfgang</creatorcontrib><creatorcontrib>Bästlein, Elke</creatorcontrib><creatorcontrib>Eimiller, Albert</creatorcontrib><creatorcontrib>Hatz, Rudolf</creatorcontrib><creatorcontrib>Lehn, Norbert</creatorcontrib><creatorcontrib>Dirschedl, Peter</creatorcontrib><creatorcontrib>Stolte, Manfred</creatorcontrib><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with that achieved with “triple therapy.” Methods In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131). Results Cure rates of H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in H. pylori -negative and 49% in H. pylori-positive patients. Conclusions The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amoxicillin - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Duodenal Ulcer - drug therapy</subject><subject>Duodenal Ulcer - etiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Germany</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - administration &amp; dosage</subject><subject>Other diseases. Semiology</subject><subject>Recurrence</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN-LFSEUxyVattvWf1DgQ0Q9zKaOztWXhdh-7MJCL_Usjh7JcMZJnXa3vz6He7mPgejB8zlfDh-EXlFySQkdPpB2dYJI8U6J94oMUnX8CdpRwWTXeuwp2p2QZ-h5Kb8IIaqX9Byd7_dMDX2_Q_ef0jpG6MYYZodrDibi5HGaYMnmb4qATfs3U3oINsQG4ZqwXTPgG4jBptHYChkvjzHlgMPswdaQ5lbhxdQAcy34PtSf2K3JwdzS12ghlxfozJtY4OXxvUA_vnz-fn3T3X37env98a6zvGe1G0EJ6yVjkvSDJxy4kGD9ICwhzhHqODAulXOSA6HSskGCUXaruPJ831-gt4fcJaffK5Sqp1AsxGhmSGvRTUTf0kUD-QG0OZWSweslh8nkR02J3nzrTabeZGrVzuZb8zb2-pi_jhO409BRcOu_OfZNsSb6bGYbygnrBWOUbDFXBwyaiz8Bsi62ybPgQm5GtUvh_3v8A8LknaQ</recordid><startdate>19950501</startdate><enddate>19950501</enddate><creator>Bayerdörffer, Ekkehard</creator><creator>Miehlke, Stephan</creator><creator>Mannes, Gerd A.</creator><creator>Sommer, Albrecht</creator><creator>Höchter, Wilhelm</creator><creator>Weingart, Josef</creator><creator>Heldwein, Walter</creator><creator>Klann, Hermann</creator><creator>Simon, Thomas</creator><creator>Schmitt, Wolfgang</creator><creator>Bästlein, Elke</creator><creator>Eimiller, Albert</creator><creator>Hatz, Rudolf</creator><creator>Lehn, Norbert</creator><creator>Dirschedl, Peter</creator><creator>Stolte, Manfred</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950501</creationdate><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><author>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amoxicillin - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Duodenal Ulcer - drug therapy</topic><topic>Duodenal Ulcer - etiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Germany</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - administration &amp; dosage</topic><topic>Other diseases. Semiology</topic><topic>Recurrence</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayerdörffer, Ekkehard</creatorcontrib><creatorcontrib>Miehlke, Stephan</creatorcontrib><creatorcontrib>Mannes, Gerd A.</creatorcontrib><creatorcontrib>Sommer, Albrecht</creatorcontrib><creatorcontrib>Höchter, Wilhelm</creatorcontrib><creatorcontrib>Weingart, Josef</creatorcontrib><creatorcontrib>Heldwein, Walter</creatorcontrib><creatorcontrib>Klann, Hermann</creatorcontrib><creatorcontrib>Simon, Thomas</creatorcontrib><creatorcontrib>Schmitt, Wolfgang</creatorcontrib><creatorcontrib>Bästlein, Elke</creatorcontrib><creatorcontrib>Eimiller, Albert</creatorcontrib><creatorcontrib>Hatz, Rudolf</creatorcontrib><creatorcontrib>Lehn, Norbert</creatorcontrib><creatorcontrib>Dirschedl, Peter</creatorcontrib><creatorcontrib>Stolte, Manfred</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayerdörffer, Ekkehard</au><au>Miehlke, Stephan</au><au>Mannes, Gerd A.</au><au>Sommer, Albrecht</au><au>Höchter, Wilhelm</au><au>Weingart, Josef</au><au>Heldwein, Walter</au><au>Klann, Hermann</au><au>Simon, Thomas</au><au>Schmitt, Wolfgang</au><au>Bästlein, Elke</au><au>Eimiller, Albert</au><au>Hatz, Rudolf</au><au>Lehn, Norbert</au><au>Dirschedl, Peter</au><au>Stolte, Manfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1995-05-01</date><risdate>1995</risdate><volume>108</volume><issue>5</issue><spage>1412</spage><epage>1417</epage><pages>1412-1417</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with that achieved with “triple therapy.” Methods In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131). Results Cure rates of H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in H. pylori -negative and 49% in H. pylori-positive patients. Conclusions The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7729633</pmid><doi>10.1016/0016-5085(95)90689-4</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0016-5085
ispartof Gastroenterology (New York, N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417
issn 0016-5085
1528-0012
language eng
recordid cdi_proquest_miscellaneous_77232285
source MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection
subjects Adolescent
Adult
Aged
Amoxicillin - administration & dosage
Biological and medical sciences
Double-Blind Method
Drug Therapy, Combination
Duodenal Ulcer - drug therapy
Duodenal Ulcer - etiology
Female
Gastroenterology. Liver. Pancreas. Abdomen
Germany
Helicobacter Infections - complications
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Male
Medical sciences
Middle Aged
Omeprazole - administration & dosage
Other diseases. Semiology
Recurrence
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
title Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Double-blind%20trial%20of%20omeprazole%20and%20amoxicillin%20to%20cure%20Helicobacter%20pylori%20infection%20in%20patients%20with%20duodenal%20ulcers&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Bayerd%C3%B6rffer,%20Ekkehard&rft.date=1995-05-01&rft.volume=108&rft.issue=5&rft.spage=1412&rft.epage=1417&rft.pages=1412-1417&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1016/0016-5085(95)90689-4&rft_dat=%3Cproquest_cross%3E77232285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77232285&rft_id=info:pmid/7729633&rft_els_id=0016508595906894&rfr_iscdi=true